Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 6
2017 16
2018 43
2019 22
2020 34
2021 41
2022 35
2023 31
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis.
Cerrato C, Crocerossa F, Marchioni M, Giannarini G, Gupta S, Albiges L, Brouwer O, Albersen M, Fankhauser C, Grimm MO, Gandaglia G, Roupret M, Mir MC; ESOU Board. Cerrato C, et al. Among authors: marchioni m. Eur Urol Oncol. 2024 Apr 20:S2588-9311(24)00096-8. doi: 10.1016/j.euo.2024.03.014. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38644155 Review.
Diagnostic Biopsy for Small Renal Tumours: A Survey of Current European Practice.
Warren H, Rautio A, Marandino L, Pyrgidis N, Tzelves L, Roussel E, Muselaers S, Erdem S, Palumbo C, Amparore D, Wu Z, Ciccarese C, Diana P, Borregales L, Pavan N, Pecoraro A, Caliò A, Klatte T, Carbonara U, Marchioni M, Bertolo R, Campi R, Tran MGB. Warren H, et al. Among authors: marchioni m. Eur Urol Open Sci. 2024 Mar 2;62:54-60. doi: 10.1016/j.euros.2024.02.002. eCollection 2024 Apr. Eur Urol Open Sci. 2024. PMID: 38585205 Free PMC article.
Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.
Meagher MF, Minervini A, Mir MC, Cerrato C, Rebez G, Autorino R, Hampton L, Campi R, Kriegmair M, Linares E, Hevia V, Musquera M, D'Anna M, Roussel E, Albersen M, Pavan N, Claps F, Antonelli A, Marchioni M, Paksoy N, Erdem S, Derweesh IH. Meagher MF, et al. Among authors: marchioni m. Eur Urol Open Sci. 2024 Mar 25;63:71-80. doi: 10.1016/j.euros.2024.02.001. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38572300 Free PMC article.
The prognostic role of histomorphological subtyping in nonmetastatic papillary renal cell carcinoma after curative surgery: is subtype really irrelevant? A propensity score matching analysis of a multi-institutional real life data.
Erdem S, Bertolo R, Campi R, Capitanio U, Amparore D, Anceschi U, Mir MC, Roussel E, Pavan N, Carbonara U, Kara O, Klatte T, Marchioni M, Pecoraro A, Muselaers S, Marandino L, Diana P, Borregales L, Palumbo C, Warren H, Wu Z, Calio A, Ciccarese C, Degirmenci E, Aydin R, Rebez G, Schips L, Simone G, Minervini A, Serni S, Ozcan F. Erdem S, et al. Among authors: marchioni m. Urol Oncol. 2024 May;42(5):163.e1-163.e13. doi: 10.1016/j.urolonc.2024.01.028. Epub 2024 Mar 5. Urol Oncol. 2024. PMID: 38443238
Metastatic de-novo renal cell carcinoma in the era of immune combinations: what can we learn from real-world data?
Francolini G, Marandino L, Ciccarese C, Pecoraro A, Amparore D, Campi R; European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group. Francolini G, et al. Minerva Urol Nephrol. 2024 Feb;76(1):120-123. doi: 10.23736/S2724-6051.23.05640-9. Minerva Urol Nephrol. 2024. PMID: 38426426 Free article. No abstract available.
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database.
Porreca A, Di Nicola M, Lucarelli G, Dorin VM, Soria F, Terracciano D, Mistretta FA, Luzzago S, Buonerba C, Cantiello F, Mari A, Minervini A, Veccia A, Antonelli A, Musi G, Hurle R, Busetto GM, Del Giudice F, Ferretti S, Perdonà S, Prete PD, Porreca A, Bove P, Crisan N, Russo GI, Damiano R, Amparore D, Porpiglia F, Autorino R, Piccinelli M, Brescia A, Tătaru SO, Crocetto F, Giudice AL, de Cobelli O, Schips L, Ferro M, Marchioni M. Porreca A, et al. Among authors: marchioni m. Urol Oncol. 2024 Mar;42(3):69.e17-69.e25. doi: 10.1016/j.urolonc.2024.01.001. Epub 2024 Feb 1. Urol Oncol. 2024. PMID: 38302296 Free article.
"Sutureless success:" can new devices make renorrhaphy after partial nephrectomy obsolete?
Roussel E, Amparore D, Bertolo R, Pecoraro A, Campi R, Mottrie A; European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group. Roussel E, et al. Minerva Urol Nephrol. 2023 Dec;75(6):788-790. doi: 10.23736/S2724-6051.23.05642-2. Minerva Urol Nephrol. 2023. PMID: 38126295 No abstract available.
The World Health Organization 2022 Classification of renal tumors: key updates for urologists.
Caliò A, Amparore D, Roussel E, Bertolo R, Erdem S, Marchioni M, Pavan N, Campi R; EAU Young Academic Urologists (YAU) Renal Cancer working group. Caliò A, et al. Among authors: marchioni m. Minerva Urol Nephrol. 2023 Dec;75(6):766-769. doi: 10.23736/S2724-6051.23.05434-4. Minerva Urol Nephrol. 2023. PMID: 38126288 No abstract available.
195 results